natgillin/translations-raw huggingface dataset:
The test must not be used in patients with documented or suspected gastric infection or atrophic gastritis, which might interfere with the urea breath test (see section 4.2).
Testa ne smete uporabiti pri bolnikih, ki imajo (ali sumite, da imajo) okužbo želodčne sluznice ali atrofični gastritis, ki lahko vplivata na sečninski dihalni test (glejte poglavje 4.2 – Odmerjanje in način uporabe).
The test must not be used in patients with documented or suspected gastric infection or atrophic gastritis, which might interfere with the urea breath test (see section 4.2).
Testa ne smete uporabiti pri bolnikih, ki imajo ali sumite, da imajo okužbo želodčne sluznice ali atrofični gastritis, ki lahko vplivata na sečninski dihalni test (glejte poglavje 4.2).
The test procedure involves the following steps:
Testni postopek obsega sledeče korake:
The test procedure lasts approximately 40 minutes.
Testni postopek traja približno 40 minut.
The test procedure takes approximately 40 minutes.
Postopek testiranja traja približno 40 minut.
The test results can suggest poor blood clotting when, in fact, there is no problem.
Testi lahko prikažejo slabo strjevanje krvi, čeprav težav sploh ni.
The test should be carried out after having fasted 6 hours before application, preferably overnight.
Pred uporabo testa se morate postiti vsaj 6 ur, najbolje čez noč.
The test should be performed following at least:
Test lahko opravite:
The test starts with the collection of samples for the determination of baseline-value (00-minute- value):
Postopek pričnemo z zbiranjem vzorcev za določitev začetne vrednosti (00-minutne vrednosti):
The tested dose of fluvoxamine was 50 mg.
Preiskovani odmerek fluvoksamina je bil 50 mg.
the testing of each donation and pools of plasma for signs of virus/infections, inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses.
preiskovanje vsake darovane in zbrane plazme za znake virusa/okužb, vključitev korakov pri obdelavi krvi ali plazme, ki lahko inaktivirajo ali odstranijo viruse.
the testing of each donation and pools of plasma for signs of virus/infections, the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses.
preiskovanje vsake darovane in zbrane plazme za znake virusa/okužb, vključevanje korakov pri obdelavi krvi ali plazme, ki lahko deaktivirajo ali odstranijo viruse.
the testing of each donation and pools of plasma for signs of virus/infections, the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses.
testiranje vsakega darovanega materiala in zbirov plazme na znake virusov/okužb, vključitev korakov, ki lahko inaktivirajo ali odstranijo viruse, v obdelavo krvi ali plazme.
the testing of each donation and pools of plasma for signs of viruses/infections. the inclusion of steps in the processing of the blood and plasma that can inactivate or remove viruses.
pregledovanje posameznih darovanih količin in zbirov plazme na znake prisotnosti virusov/okužb, vključitev korakov v postopke obdelave krvi in plazme, ki lahko viruse inaktivirajo ali odstranijo.
the testing of samples of donated blood and plasma to try to avoid use of material with signs of virus/infections, the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses.
testiranje vzorcev darovane krvi in plazme, da se poskusi preprečiti uporaba materialov z znaki virusov/okužb, vključitev korakov priprave krvi in plazme, kjer se virusi inaktivirajo ali odstranijo.
The tests included 1,776 patients at risk of thromboembolism taking enoxaparin in preventing venous thromboembolism after orthopaedic or abdominal surgery, 1,169 patients bedridden due to acute medical illness, given enoxaparin in preventing venous thromboembolism, 559 patients administered enoxaparin in the treatment of DVT, complicated or uncomplicated by pulmonary embolism, 1,578 patients receiving enoxaparin in the treatment of unstable angina and non-Q-wave myocardial infarction and 10,176 patients receiving enoxaparin in the treatment of acute ST segment elevation myocardial infarction.
Ta so obsegala 1.176 primerov jemanja enoksaparina za preprečevanje venske trombembolije po ortopedski ali abdominalni operaciji pri bolnikih s tveganjem za trombembolične zaplete, 1.169 primerov jemanja enoksaparina za preprečevanje venske trombembolije pri akutnih nekirurških bolnikih z zelo omejeno gibljivostjo, 559 primerov jemanja enoksaparina za zdravljenje GVT s pljučno embolijo ali brez nje, 1.578 primerov jemanja enoksaparina za zdravljenje nestabilne angine pektoris in miokardnega infarkta brez zobca Q ter 10.176 primerov jemanja enoksaparina za zdravljenje miokardnega infarkta z akutnim dvigom spojnice ST.
The Thalidomide Celgene Pregnancy Prevention Programme reinforces the warnings about the teratogenicity of thalidomide, provides advice on contraception before therapy is started and provides guidance on the need for pregnancy testing.
Program Thalidomide Celgene za preprečevanje nosečnosti poudarja opozorila o teratogenosti talidomida ter nudi nasvete glede kontracepcije pred začetkom zdravljenja in navodila glede potrebe po testu nosečnosti.
The the number of units is shown in the dose window of the pen regardless of strength and no dose conversion should be done when transferring a patient to a new strength.
Število enot je prikazano v okencu za prikaz odmerka na injekcijskem peresniku, ne glede na jakost, in ob prehodu bolnika na novo jakost se ne sme izvajati pretvorbe odmerka.
The theoretical specific activity is 4110 GBq/mg of Lutetium (177Lu).
Teoretična specifična aktivnost je 4 110 GBq/mg lutecija (177Lu).
The therapeutic benefits of a reduction in growth hormone (GH) levels and normalisation of insulin-like growth factor 1 (IGF-1) concentration in female acromegalic patients could potentially restore fertility.
Znižanje koncentracije rastnega hormona in normalizacija koncentracije insulinu podobnega rastnega faktorja-1 (IGF-1) zaradi zdravljenja bi ženskim bolnicam z akromegalijo lahko povrnilo plodnost.
The therapeutic benefits of a reduction in IGF-I concentration which results in improvement of the patient’s clinical condition could potentially increase fertility in female patients.
Terapevtsko ugodno zmanjšanje koncentracije IGF-I, ki izboljša klinično stanje bolnikov, lahko pri bolnicah morda zveča plodnost.
The therapeutic benefits of a reduction or normalisation of serum cortisol levels in female patients with Cushing’s disease could potentially restore fertility.
Znižanje ali normalizacija vrednosti kortizola v serumu zaradi zdravljenja bi lahko bolnicam s Cushingovo boleznijo povrnilo plodnost.
The therapeutic benefits of enoxaparin, seen as a better performance efficacy, appeared after 48 hours.
Koristi zdravljenja z enoksaparinom, ki so se kazale z izboljšano učinkovitostjo, so se pojavile po 48 urah.
The therapeutic effect is mediated through the generation of highly reactive oxygen species, a process dependent on the intracellular interaction of temoporfin with light and oxygen.
Terapevtski učinek se posreduje z generiranjem visoko reaktivnih kisikovih spojin, procesom, ki je odvisen od znotrajcelične interakcije temoporfina s svetlobo in kisikom.
The therapeutic experience in patients ≥75 years of age is limited.
Izkušnje pri zdravljenju bolnikov, starih 75 let ali več, so omejene.
The therapeutic experience with Xultophy in patients with hepatic impairment is currently too limited to recommend the use in these patients (see section 5.2).
Terapevtskih izkušenj pri zdravljenju bolnikov z okvaro jeter je trenutno premalo, da bi zdravilo lahko priporočili za zdravljenje teh bolnikov (glejte poglavje 5.2).
The therapeutic goal of treatment with antithrombin alfa is to increase to, and maintain antithrombin activity between 80 – 120% (0.8 – 1.2 IU/ml) for the duration of treatment.
Terapevtski namen zdravljenja z antitrombinom alfa je povečati in vzdrževati aktivnost antitrombina med 80–120 % (0,8–1,2 i.e./ml) v času zdravljenja.
The therapeutic goal of treatment with antithrombin alfa is to increase to, and maintain antithrombin activity between 80 – 120% of normal (0.8 – 1.2 IU/ml) for the duration of treatment.
Terapevtski namen zdravljenja z antitrombinom alfa je povečati in vzdrževati aktivnost antitrombina med normalno vrednostjo 80–120 % (0,8–1,2 i.e./ml) v času zdravljenja.
The therapeutic range of MIRCERA is wide.
Zdravilo MIRCERA ima široko terapevtsko okno.
The therapy is recommended as 2 treatment courses (see posology) with safety follow-up of patients from initiation of treatment and until 48 months after the last infusion (see section 4.4).
Zdravljenje se priporoča v obliki 2 ciklov zdravljenja (glejte poglavje o odmerjanju) z varnostnim sledenjem bolnikov od uvedbe zdravljenja do 48 mesecev po zadnji infuziji (glejte poglavje 4.4).
The therapy should be continued for up to 4 weeks after the end of chemotherapy.
Zdravljenje nadaljujemo do 4 tedne po končani kemoterapiji.
The therapy should be initiated by a doctor experienced in the management of HIV infection (see also section 4.4).
Zdravljenje mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV (glejte tudi poglavje 4.4).
the thigh
za injiciranje je sprednja
The thigh, the gluteal region or the deltoid region may also be used.
Uporabiti pa je mogoce tudi stegno, glutealni predel ali deltoidni predel.
The thioguanine nucleotides are also incorporated into nucleic acids and this contributes to the cytotoxic effects of the active substance.
Nukleotidi tiogvanina so tudi vgrajeni v nukleinske kisline, kar vpliva na citotoksične učinke zdravilne učinkovine.
The third active substance, ritonavir, does not act directly against hepatitis C virus but it blocks the action of an enzyme called CYP3A that breaks down paritaprevir.
Tretja zdravilna učinkovina, ritonavir, ne deluje neposredno proti virusu hepatitisa C, temveč zavira delovanje encima, imenovanega CYP3A, ki razgrajuje paritaprevir.
The third clinical study showed that the administration of 2 doses with a 2 month interval starting at 36-46 months of age resulted in higher ELISA antibody GMCs and OPA GMTs than those observed one month after a 3 dose primary vaccination for each vaccine serotype and the cross-reactive serotype 19A. The proportion of subjects with an ELISA antibody concentration ≥ 0.20 µg/mL or an OPA
Tretja klinična študija je pokazala, da je uporaba 2 odmerkov v presledku 2 mesecev in z začetkom v starosti od 36 do 46 mesecev povzročila višje GMC protiteles z ELISA in GMT OPA za vsakega od serotipov v cepivu in za navzkrižno reaktivni serotip 19A, kot so bile ugotovljene en mesec po primarnem cepljenju s 3 odmerki.
The third group received 40 mg of Humira every other week with placebo injections on alternate weeks.Upon completion of the first 52 weeks, 457 patients enrolled in an open- label extension phase in which 40 mg of Humira/MTX was administered every other week up to 10 years.
Po zaključenih prvih 52 tednih so 457 bolnikov vključili v odprto nadaljevalno fazo, med katero so dobivali 40 mg zdravila Humira/MTX vsak drugi teden v obdobju do 10 let.
The third group received 40 mg of Humira every other week with placebo injections on alternate weeks.Upon completion of the first 52 weeks, 457 patients enrolled in an open- label extension phase in which 40 mg of Humira/MTX was administered every other week up to 10 years.
Po zaključenih prvih 52 tednih so 457 bolnikov vključili v odprto nadaljevalno fazo, med katero so dobivali 40 mg zdravilo Humira/MTX vsak drugi teden v obdobju do 10 let.
The third method is application of Raplixa onto the bleeding site using the recommended spray device followed by the application of the gelatin sponge.
Tretja metoda je nanos zdravila Raplixa na mesto krvavitve s priporočenim pršilnikom, ki mu sledi nanos želatinske gobice.
The third patient experienced nausea, vomiting and hot flushes after 3.6 mg IM dose.
Pri tretjem bolniku so se po prejemu i.m. odmerka 3,6 mg pojavili: navzea, bruhanje in vročinski oblivi.
The third study compared Lucentis with verteporfin photodynamic therapy (PDT, another treatment for AMD).
V tretji študiji so zdravilo Lucentis primerjali s fotodinamično terapijo z verteporfinom (PDT, drugo obliko zdravljenja starostne degeneracije makule).
The third study compared Myocet with epirubicin (another anthracycline), both in combination with cyclophosphamide, in 160 women.
V tretji študiji so pri 160 ženskah zdravilo Myocet primerjali z epirubicinom (drugim antraciklinom), obe zdravili pa so dajali skupaj s ciklofosfamidom.
The third study compared two weeks of Xarelto with two weeks of enoxaparin in around 2,500 patients undergoing knee replacement surgery.
V tretji študiji so pri okoli 2 500 bolnikih po kirurški zamenjavi kolena dvotedensko jemanje zdravila Xarelto primerjali z dvotedenskim jemanjem enoksaparina.
The third study did not support the early use of Tarceva in lung cancer patients without EGFR activating mutations, including patients with stable disease: the study found no advantage to early use of the medicine, as patients treated with Tarceva early in the study did not live longer than those treated with Tarceva later in the study (after the disease had progressed).
V tretji študiji niso bili ugotovljeni pozitivni učinki zgodnjega jemanja zdravila Tarceva pri bolnikih s pljučnim rakom brez EGFR-aktivirajočimi mutacijami, vključno z bolniki s stabilno boleznijo: v študiji niso dokazali nobene prednosti zgodnejšega jemanja zdravila, saj bolniki, ki so zdravilo Tarceva začeli jemati na začetku študije, niso živeli dlje od bolnikov, ki so se z zdravilom Tarceva začeli zdraviti pozneje v študiji (potem ko se je bolezen že poslabšala).
The third study in pigs showed that after treatment with Panacur AquaSol the number of Trichuris suis eggs was reduced by 90%.
Tretja študija pri prašičih je pokazala, da se je število jajčec Trichuris suis po zdravljenju z zdravilom Panacur AquaSol zmanjšalo za 90 %.
The third study included 459 patients who had been taking three antiviral medicines (including lamivudine) for at least 12 weeks and had low levels of HIV in their blood.
Tretja študija je vključevala 459 bolnikov, ki so vsaj 12 tednov prejemali tri protivirusna zdravila (vključno z lamivudinom) in so imeli nizke ravni HIV v krvi.
The third study involved 1,776 patients with advanced solid tumours in various parts of the body, excluding the breast or the prostate, or with multiple myeloma (a cancer of the bone marrow).
V tretjo študijo je bilo vključenih 1 776 bolnikov z napredovalim solidnim tumorjem na različnih delih telesa razen na dojkah ali prostati ali oseb z multiplim mielomom (rakom kostnega mozga).
The third study involved 100 children, who were given one of two doses of Kaletra oral solution.
Tretja študija je vključevala 100 otrok, ki so prejemali enega od obeh odmerkov peroralne raztopine Kaletra.
The third study involved 296 women with metastatic disease that got worse despite treatment with other cancer medicines (including anthracyclines and taxanes) and with combinations of cancer medicines plus trastuzumab.
V tretjo študijo je bilo vključenih 296 žensk z metastatsko boleznijo, ki se je slabšala kljub zdravljenju z drugimi zdravili proti raku (vključno z antraciklini in taksani) in s kombinacijami drugih zdravil proti raku in trastuzumaba.
The third study involved 30 patients with aHUS who had already received at least one dose of eculizumab.
Tretja študija je vključevala 30 bolnikov z atipičnim hemolitično-uremičnim sindromom, ki so že prejeli vsaj en odmerek ekulizumaba.
The third study involved 416 patients with advanced renal cell carcinoma that had got worse despite treatment with certain VEGF-targeted medicines (sunitinib, sorafenib or both).
Tretja študija je vključevala 416 bolnikov z napredovalim rakom ledvičnih celic, ki se je poslabšal kljub zdravljenju z zdravili, ki so usmerjena proti žilnemu endotelijskemu rastnemu dejavniku (sunitinibom, sorafenibom ali kombinacijo obeh).
The third study involved 438 patients whose blood glucose was not adequately controlled by a combination of a GLP-1 agonist (liraglutide or exenatide) and metformin with or without other diabetes medicines taken by mouth.
Tretja študija je vključevala 438 bolnikov, pri katerih raven glukoze v krvi ni bila zadostno uravnavana z jemanjem kombinacije antagonista GLP-1 (liraglutida ali eksenatida) in metformina ne glede na to, ali so jemali druga zdravila za peroralno uporabo za zdravljenje sladkorne bolezni, ali jih niso.
The third study involved 59 children aged two to 12 years.
V tretji študiji je sodelovalo 59 otrok, starih od dve do 12 let.
The third study involved 829 patients who had failed previous treatment including a fluoropyrimidine and irinotecan (other chemotherapy medicines).
V tretjo študijo je bilo vključenih 829 bolnikov, pri katerih predhodno zdravljenje, ki je vključevalo fluoropirimidin in irinotekan (drugi zdravili za kemoterapijo), ni bilo uspešno.
The third study involved women in the age range 35 to 42 years weighing 50 kg or more who were given a 150-microgram dose of Elonva; the main measure of effectiveness in this study was the number of women with a successful early pregnancy.
V tretji študiji, v kateri so sodelovale ženske, stare od 35 do 42 let, s telesno maso nad 50 kg, so ženskam dajali 150-mikrogramski odmerek zdravila Elonva; glavno merilo učinkovitosti v tej študiji je bilo število žensk, ki so uspešno prestale zgodnjo fazo nosečnosti.
The third study reported no difference in risk of psychiatric adverse events diagnosed during an emergency department visit or inpatient admission between varenicline users and bupropion users (HR 0.85; 95% CI: 0.55-1.30).
V tretji študiji med uporabniki vareniklina in uporabniki bupropiona niso poročali o razlikah v tveganju za pojav psihiatričnih neželenih učinkov, ki so jih diagnosticirali med obiskom oddelka za nujno medicinsko pomoč ali hospitalizacijo (HR 0,85; 95 % IZ: 0,55–1,30).
The third study showed a fall in blood pressure of 8.5 mmHg with Rasilamlo 150/5 mg compared with
V tretji študiji se je pri jemanju zdravila Rasilamlo v odmerku 150/5 mg krvni tlak znižal za 8,5 mmHg v primerjavi z 8,0 mmHg oz.
The third study showed that 21 days after the second injection, around 70% of adults below 60 years and around 64% of adults above 60 years produced an acceptable antibody response.
Tretja študija je pokazala, da je 21 dni po drugi injekciji pri okoli 70 % odraslih, mlajših od 60 let, in okoli 64 % odraslih, starejših od 60 let, prišlo do zadovoljivega odziva protiteles.
The third study showed that in patients treated with Incivo, giving peginterferon alfa and ribavirin for six months was as effective as giving these medicines for one year, since 92% of patients receiving them for six months tested negative for hepatitis C compared with 88% of patients receiving them for one year.
Rezultati tretje študije so pokazali, da je bilo zdravljenje bolnikov z zdravilom Incivo, ki so šest mesecev jemali peginterferon alfa in ribavirin, enako učinkovito kot enoletno zdravljenje s tema zdraviloma, saj je bil pri 92 % bolnikov, ki so navedena zdravila prejemali šest mesecev, izvid za hepatitis C negativen v primerjavi z 88 % bolnikov, ki so peginterferon alfa in ribavirin prejemali eno leto.
The third study showed that the immune response triggered by M-M-RVAXPRO was the same regardless of whether it was injected into a muscle or under the skin.
Tretja študija je pokazala, da je imunski odziv, ki ga je sprožilo cepivo M-M-RVAXPRO, enak ne glede na to, ali je cepivo injicirano v mišico ali pod kožo.
The third study was done in 278 patients with genotypes 2 or 3 hepatitis C virus who could not take or did not want to have treatment with interferon.
Tretjo študijo so opravili na 278 bolnikih z virusom hepatitisa C genotipa 2 ali 3, ki se niso mogli ali se niso želeli zdraviti z interferonom.
The third trimester of pregnancy and breast-feeding (see sections 4.6 and 5.3).
v tretjem trimesečju nosečnosti in obdobju dojenja (glejte poglavji 4.6 in 5.3),
The Thorinane pre-filled syringes are for single dose use only; discard any unused medicinal product.
Napolnjene injekcijske brizge zdravila Thorinane so vsebniki s posamičnim odmerkom.
The Thorinane pre-filled syringes are for single dose use only; discard any unused medicinal product.
Napolnjene injekcijske brizge zdravila Thorinane vsebujejo en sam odmerek.
The three active ingredients in the veterinary medicine act by contact on the parasites.
Tri zdravilne učinkovine v zdravilu za uporabo v veterinarski medicini delujejo preko kontakta s parazitom.
The three active substances rapidly distribute over the body surface of the animal within the first day, with maximum concentrations obtained 3 days after the application.
Tri zdravilne učinkovine se hitro razporedijo po površini telesa živali v prvem dnevu, maksimalno koncentracijo dosežejo 3 dni po nanosu.
The three active substances were still measurable in different zones of the hair coat one month after treatment.
Tri zdravilne učinkovine so bile izmerjene v različnih predelih dlake še en mesec po nanosu.
The three most frequent non-haematological adverse reactions were dizziness (15.5%), constipation (8.2%) and herpes zoster (6.4%).
Trije najbolj pogosti nehematološki neželeni učinki so bili omotičnost (15,5 %), obstipacija (8,2 %) in herpes zoster (6,4 %).
The three most frequent non-haematological laboratory abnormalities (any CTCAE grade) were hypercholesterolaemia (30.0%), raised alanine aminotransferase (22.7%) and raised aspartate aminotransferase (20.9%).
Tri najbolj pogoste nehematološke patološke laboratorijske vrednosti (katerekoli stopnje po CTCAE) so bile hiperholesterolemija (30,0 %), zvišana vrednost alanin-aminotransferaze (22,7 %) in zvišana vrednost aspartat-aminotransferaze (20,9 %).
The three most frequent non-haematological laboratory abnormalities were raised alanine aminotransferase (27.2%), raised aspartate aminotransferase (19.9%) and hypercholesterolaemia (16.9%).
Tri najbolj pogoste nehematološke patološke laboratorijske vrednosti so bile zvišana vrednost alanin-aminotransferaze (27,2 %), zvišana vrednost aspartat-aminotransferaze (19,9 %) in hiperholesterolemija (16,9 %).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 12).
Za injiciranje zdravila Enbrel so priporočljiva tri injekcijska mesta: (1) na sredini sprednjega dela stegna; (2) na trebuhu, razen v predelu 5 cm okrog popka; in (3) na zunanjem delu nadlakti (glejte sliko 12).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 17).
Za injiciranje zdravila Enbrel so priporočljiva tri injekcijska mesta: (1) na sredini sprednjega dela stegna; (2) na trebuhu, razen v predelu 5 cm okrog popka; in (3) na zunanjem delu nadlakti (glejte sliko 17).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 9).
Za injiciranje zdravila Enbrel so priporočljiva tri injekcijska mesta: (1) na sredini sprednjega dela stegna; (2) na trebuhu, razen v predelu 5 cm okrog popka; in (3) na zunanjem delu nadlakti (glejte sliko 9).
The three-month standard pack contains 168 x 30 mg tablets.
Trimesečno standardno pakiranje vsebuje 168 x 30 mg tablet.
The three-month treatment course can be repeated.
Trimesečno zdravljenje se lahko ponovi.
The threshold concentration required is dependent on the organism and the amount and type of β-lactamase produced.
Mejna vrednost koncentracije, ki je potrebna, je odvisna od organizma, količine in tipa tvorjene betalaktamaze.
The threshold of 20 mg/l was reached for cumulative amounts of mitotane of approximately 500 g.
363 g) Pražna vrednost 20 mg/l je bila dosežena pri kumulativni količini mitotana približno 500 g.